Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Lung Cancer

Free Subscription Articles published in Cancer Res Retrieve available abstracts of 193 articles: HTML format

Single Articles

March 2021
1. ANCEY PB, Contat C, Boivin G, Sabatino S, et al
   Glut1 expression in tumor-associated neutrophils promotes lung cancer growth and resistance to radiotherapy.
   Cancer Res. 2021 Mar 22. pii: 0008-5472.CAN-20-2870.
   PubMed     Abstract available
   
   
   
2. YANG Z, Liang SQ, Yang H, Xu D, et al
   CRISPR-mediated kinome editing prioritizes a synergistic combination therapy for FGFR1-amplified lung cancer.
   Cancer Res. 2021 Mar 8. pii: 0008-5472.CAN-20-2276.
   PubMed     Abstract available
   
   
   
3. WANG X, Ricciuti B, Nguyen T, Li X, et al
   Association between smoking history and tumor mutation burden in advanced non-small cell lung cancer.
   Cancer Res. 2021 Mar 2. pii: 0008-5472.CAN-20-3991.
   PubMed     Abstract available
   
   
   February 2021
4. DAGNINO S, Bodinier B, Guida F, Smith-Byrne K, et al
   Prospective identification of elevated circulating CDCP1 in patients years before onset of lung cancer.
   Cancer Res. 2021 Feb 11. pii: 0008-5472.CAN-20-3454.
   PubMed     Abstract available
   
   
   
5. DAVENPORT ML, Echols JB, Silva AD, Anderson JC, et al
   miR-31 displays subtype specificity in lung cancer.
   Cancer Res. 2021 Feb 8. pii: 0008-5472.CAN-20-2769.
   PubMed     Abstract available
   
   
   
6. SCHAFF DL, Singh S, Kim KB, Sutcliffe MD, et al
   Fragmentation of Small-cell Lung Cancer Regulatory States in Heterotypic Microenvironments.
   Cancer Res. 2021 Feb 2. pii: 0008-5472.CAN-20-1036.
   PubMed     Abstract available
   
   
   
7. BOSHUIZEN J, Pencheva N, Krijgsman O, D'Empaire Altimari D, et al
   Cooperative targeting of immunotherapy-resistant melanoma and lung cancer by an AXL-targeting antibody-drug conjugate and immune checkpoint blockade.
   Cancer Res. 2021 Feb 2. pii: 0008-5472.CAN-20-0434.
   PubMed     Abstract available
   
   
   January 2021
8. ZHU M, Huang Y, Bender ME, Girard L, et al
   Evasion of Innate Immunity Contributes to Small Cell Lung Cancer Progression and Metastasis.
   Cancer Res. 2021 Jan 25. pii: 0008-5472.CAN-20-2808.
   PubMed     Abstract available
   
   
   
9. MONTEVERDE T, Sahoo S, La Montagna M, Magee P, et al
   CKAP2L promotes non-small cell lung cancer progression through regulation of transcription elongation.
   Cancer Res. 2021 Jan 20. pii: 0008-5472.CAN-20-1968.
   PubMed     Abstract available
   
   
   
10. HUNG RJ, Warkentin MT, Brhane Y, Chatterjee N, et al
    Assessing Lung Cancer Absolute Risk Trajectory based on a Polygenic Risk Model.
    Cancer Res. 2021 Jan 20. pii: 0008-5472.CAN-20-1237.
    PubMed     Abstract available
    
    
    December 2020
11. LA FLEUR L, Botling J, He F, Pelicano C, et al
    Targeting MARCO and IL-37R on immunosuppressive macrophages in lung cancer blocks regulatory T cells and supports cytotoxic lymphocyte function.
    Cancer Res. 2020 Dec 8. pii: 0008-5472.CAN-20-1885.
    PubMed     Abstract available
    
    
    
12. GARG R, Cooke M, Benavides F, Abba MC, et al
    PKCepsilon Is Required for KRAS-Driven Lung Tumorigenesis.
    Cancer Res. 2020;80:5166-5173.
    PubMed     Abstract available
    
    
    November 2020
13. SHEN M, Xie S, Rowicki M, Michel S, et al
    Therapeutic Targeting of Metadherin Suppresses Colorectal and Lung Cancer Progression and Metastasis.
    Cancer Res. 2020 Nov 25. pii: 0008-5472.CAN-20-1876.
    PubMed     Abstract available
    
    
    
14. CHUANG CH, Dorsch M, Dujardin P, Silas S, et al
    Altered mitochondria functionality defines a metastatic cell state in lung cancer and creates an exploitable vulnerability.
    Cancer Res. 2020 Nov 25. pii: 0008-5472.CAN-20-1865.
    PubMed     Abstract available
    
    
    
15. GUO W, Li K, Sun B, Xu D, et al
    Dysregulated Glutamate Transporter SLC1A1 Propels Cystine Uptake via Xc- for Glutathione Synthesis in Lung Cancer.
    Cancer Res. 2020 Nov 23. pii: 0008-5472.CAN-20-0617.
    PubMed     Abstract available
    
    
    
16. HARRISON EB, Porrello A, Bowman BM, Belanger AR, et al
    A Circle RNA Regulatory Axis Promotes Lung Squamous Metastasis via CDR1-Mediated Regulation of Golgi Trafficking.
    Cancer Res. 2020;80:4972-4985.
    PubMed     Abstract available
    
    
    
17. SOOTOME H, Fujita H, Ito K, Ochiiwa H, et al
    Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
    Cancer Res. 2020;80:4986-4997.
    PubMed     Abstract available
    
    
    
18. MCCLATCHY DM, Willers H, Hata AN, Piotrowska Z, et al
    Modeling Resistance and Recurrence Patterns of Combined Targeted-Chemoradiotherapy Predicts Benefit of Shorter Induction Period.
    Cancer Res. 2020;80:5121-5133.
    PubMed     Abstract available
    
    
    
19. TAGAL V, Roth MG
    Loss of Aurora kinase signaling allows lung cancer cells to adopt endoreplication and form polyploid giant cancer cells that resist antimitotic drugs.
    Cancer Res. 2020 Nov 10. pii: 0008-5472.CAN-20-1693.
    PubMed     Abstract available
    
    
    
20. SUN Y, Meyers BA, Czako B, Leonard P, et al
    Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib.
    Cancer Res. 2020;80:4840-4853.
    PubMed     Abstract available
    
    
    October 2020
21. LIU CH, Chen Z, Chen K, Liao FT, et al
    Lipopolysaccharide-mediated chronic inflammation promotes tobacco carcinogen-induced lung cancer and determines the efficacy of immunotherapy.
    Cancer Res. 2020 Oct 29. pii: 0008-5472.CAN-20-1994.
    PubMed     Abstract available
    
    
    
22. SU Y, Zhang X, Bidlingmaier S, Behrens CR, et al
    ALPPL2 Is a Highly Specific and Targetable Tumor Cell Surface Antigen.
    Cancer Res. 2020;80:4552-4564.
    PubMed     Abstract available
    
    
    
23. WONG CC, Baum J, Silvestro A, Beste MT, et al
    Inhibition of IL-1beta by canakinumab may be effective against diverse molecular subtypes of lung cancer: an exploratory analysis of the CANTOS trial.
    Cancer Res. 2020 Oct 6. pii: 0008-5472.CAN-19-3176.
    PubMed     Abstract available
    
    
    
24. SHANI O, Vorobyov T, Monteran L, Lavie D, et al
    Fibroblast-derived IL-33 facilitates breast cancer metastasis by modifying the immune microenvironment and driving type-2 immunity.
    Cancer Res. 2020 Oct 6. pii: 0008-5472.CAN-20-2116.
    PubMed     Abstract available
    
    
    
25. SANCHEZ-MAGRANER L, Miles J, Baker CL, Applebee CJ, et al
    High PD-1/PD-L1 Checkpoint Interaction Infers Tumor Selection and Therapeutic Sensitivity to Anti-PD-1/PD-L1 Treatment.
    Cancer Res. 2020;80:4244-4257.
    PubMed     Abstract available
    
    
    
26. EL-NIKHELY N, Karger A, Sarode P, Singh I, et al
    Metastasis-Associated Protein 2 Represses NF-kappaB to Reduce Lung Tumor Growth and Inflammation.
    Cancer Res. 2020;80:4199-4211.
    PubMed     Abstract available
    
    
    
27. PULIDO I, Ollosi S, Aparisi S, Becker JH, et al
    Endothelin-1-Mediated Drug Resistance in EGFR-Mutant Non-Small Cell Lung Carcinoma.
    Cancer Res. 2020;80:4224-4232.
    PubMed     Abstract available
    
    
    September 2020
28. BELLERI M, Paganini G, Coltrini D, Ronca R, et al
    BETA-GALACTOSYLCERAMIDASE PROMOTES MELANOMA GROWTH VIA MODULATION OF CERAMIDE METABOLISM.
    Cancer Res. 2020 Sep 30. pii: 0008-5472.CAN-19-3382.
    PubMed     Abstract available
    
    
    
29. KIM KB, Kim Y, Rivard CJ, Kim DW, et al
    FGFR1 is critical for Rbl2 loss-driven tumor development and requires PLCG1 activation for continued growth of small cell lung cancer.
    Cancer Res. 2020 Sep 24. pii: 0008-5472.CAN-20-1453.
    PubMed     Abstract available
    
    
    
30. MAHAUAD-FERNANDEZ WD, Felsher DW
    The Myc and Ras Partnership in Cancer: Indistinguishable Alliance or Contextual Relationship?
    Cancer Res. 2020;80:3799-3802.
    PubMed     Abstract available
    
    
    
31. GUPTA M, Concepcion CP, Fahey CG, Keshishian H, et al
    BRG1 Loss Predisposes Lung Cancers to Replicative Stress and ATR Dependency.
    Cancer Res. 2020;80:3841-3854.
    PubMed     Abstract available
    
    
    
32. GHERGUROVICH JM, Esposito M, Chen Z, Wang JZ, et al
    Glucose-6-Phosphate Dehydrogenase Is Not Essential for K-Ras-Driven Tumor Growth or Metastasis.
    Cancer Res. 2020;80:3820-3829.
    PubMed     Abstract available
    
    
    
33. LU Y, Liu Y, Oeck S, Zhang GJ, et al
    Hypoxia induces resistance to EGFR inhibitors in lung cancer cells via upregulation of FGFR1 and the MAPK pathway.
    Cancer Res. 2020 Sep 1. pii: 0008-5472.CAN-20-1192.
    PubMed     Abstract available
    
    
    
34. GHOSH P, Guo Y, Ashrafi A, Chen J, et al
    Oxygen-Enhanced Optoacoustic Tomography Reveals the Effectiveness of Targeting Heme and Oxidative Phosphorylation at Normalizing Tumor Vascular Oxygenation.
    Cancer Res. 2020;80:3542-3555.
    PubMed     Abstract available
    
    
    August 2020
35. KUO MH, Lee AC, Hsiao SH, Lin SE, et al
    Crosstalk between SOX2 and TGF-beta signaling regulates EGFR-TKI tolerance and lung cancer dissemination.
    Cancer Res. 2020 Aug 19. pii: 0008-5472.CAN-19-3228.
    PubMed     Abstract available
    
    
    
36. HAYASHI M, Kuga A, Suzuki M, Panda H, et al
    Microenvironmental Activation of Nrf2 Restricts the Progression of Nrf2-Activated Malignant Tumors.
    Cancer Res. 2020;80:3331-3344.
    PubMed     Abstract available
    
    
    
37. SHOLL LM, Oxnard GR, Paweletz CP
    Traditional Diagnostics versus Disruptive Technology: The Role of the Pathologist in the Era of Liquid Biopsy.
    Cancer Res. 2020;80:3197-3199.
    PubMed     Abstract available
    
    
    
38. ZHANG Y, Cedervall J, Hamidi A, Herre M, et al
    Platelet-Specific PDGFB Ablation Impairs Tumor Vessel Integrity and Promotes Metastasis.
    Cancer Res. 2020;80:3345-3358.
    PubMed     Abstract available
    
    
    
39. IRURZUN-ARANA I, McDonald TO, Troconiz IF, Michor F, et al
    Pharmacokinetic Profiles Determine Optimal Combination Treatment Schedules in Computational Models of Drug Resistance.
    Cancer Res. 2020;80:3372-3382.
    PubMed     Abstract available
    
    
    
40. LI Y, Zhang X, Zhu S, Dejene EA, et al
    HDAC10 Regulates Cancer Stem-Like Cell Properties in KRAS-Driven Lung Adenocarcinoma.
    Cancer Res. 2020;80:3265-3278.
    PubMed     Abstract available
    
    
    
41. QIU Z, Fa P, Liu T, Prasad CB, et al
    A Genome-Wide Pooled shRNA Screen Identifies PPP2R2A as a Predictive Biomarker for the Response to ATR and CHK1 Inhibitors.
    Cancer Res. 2020;80:3305-3318.
    PubMed     Abstract available
    
    
    
42. SHAKED MS, Dassa B, Sinha S, Di Agostino S, et al
    A division of labor between YAP and TAZ in non-small cell lung cancer.
    Cancer Res. 2020 Aug 14. pii: 0008-5472.CAN-20-0125.
    PubMed     Abstract available
    
    
    July 2020
43. ZHENG X, Weigert A, Reu S, Guenther S, et al
    Spatial Density and Distribution of Tumor-Associated Macrophages Predict Survival in Non-Small-Cell Lung Carcinoma.
    Cancer Res. 2020 Jul 22. pii: 0008-5472.CAN-20-0069.
    PubMed     Abstract available
    
    
    
44. KOGLER M, Tortola L, Negri GL, Leopoldi A, et al
    HACE1 Prevents Lung Carcinogenesis via Inhibition of RAC-Family GTPases.
    Cancer Res. 2020;80:3009-3022.
    PubMed     Abstract available
    
    
    
45. BRIDGES AE, Ramachandran S, Pathania R, Parwal U, et al
    RAD51AP1 deficiency reduces tumor growth by targeting stem cell self-renewal.
    Cancer Res. 2020 Jul 14. pii: 0008-5472.CAN-19-3713.
    PubMed     Abstract available
    
    
    
46. LI F, Ng WL, Luster TA, Hu H, et al
    Epigenetic CRISPR screens identify Npm1 as a therapeutic vulnerability in non-small cell lung cancer.
    Cancer Res. 2020 Jul 9. pii: 0008-5472.CAN-19-3782.
    PubMed     Abstract available
    
    
    
47. BAUMEISTER SE, Leitzmann MF, Bahls M, Meisinger C, et al
    Physical activity does not lower the risk of lung cancer.
    Cancer Res. 2020 Jul 9. pii: 0008-5472.CAN-20-1127.
    PubMed     Abstract available
    
    
    
48. DAI C, Charlestin V, Wang M, Walker ZT, et al
    Aquaporin-7 Regulates the Response to Cellular Stress in Breast Cancer.
    Cancer Res. 2020 Jul 6. pii: 0008-5472.CAN-19-2269.
    PubMed     Abstract available
    
    
    
49. BROWNMILLER T, Juric JA, Ivey AD, Harvey BM, et al
    Y Chromosome LncRNA are involved in Radiation Response of Male Non-Small Cell Lung Cancer Cells.
    Cancer Res. 2020 Jul 2. pii: 0008-5472.CAN-19-4032.
    PubMed     Abstract available
    
    
    
50. DIMITRAKOPOULOS FD, Kottorou AE, Kalofonou M, Kalofonos HP, et al
    The Fire Within: NF-kappaB involvement in Non-Small Cell Lung Cancer.
    Cancer Res. 2020 Jul 2. pii: 0008-5472.CAN-19-3578.
    PubMed     Abstract available
    
    
    
51. BUI NHB, Napoli M, Davis AJ, Abbas HA, et al
    Spatiotemporal Regulation of DeltaNp63 by TGFbeta-Regulated miRNAs Is Essential for Cancer Metastasis.
    Cancer Res. 2020;80:2833-2847.
    PubMed     Abstract available
    
    
    June 2020
52. ZHOU ZW, Ambrogio C, Bera AK, Li Q, et al
    KRASQ61H preferentially signals through MAPK in a RAF dimer-dependent manner in non-small cell lung cancer.
    Cancer Res. 2020 Jun 30. pii: 0008-5472.CAN-20-0448.
    PubMed     Abstract available
    
    
    
53. YANG YC, Pan KF, Lee WJ, Chang JH, et al
    Circulating proteoglycan endocan mediates EGFR-driven progression of non-small cell lung cancer.
    Cancer Res. 2020 Jun 19. pii: 0008-5472.CAN-20-0005.
    PubMed     Abstract available
    
    
    
54. VANDAMME N, Denecker G, Bruneel K, Blancke G, et al
    The EMT transcription factor ZEB2 promotes proliferation of primary and metastatic melanoma while suppressing an invasive, mesenchymal-like phenotype.
    Cancer Res. 2020 Jun 5. pii: 0008-5472.CAN-19-2373.
    PubMed     Abstract available
    
    
    
55. ZHANG Y, Shi J, Liu X, Xiao Z, et al
    H2A Monoubiquitination Links Glucose Availability to Epigenetic Regulation of the Endoplasmic Reticulum Stress Response and Cancer Cell Death.
    Cancer Res. 2020;80:2243-2256.
    PubMed     Abstract available
    
    
    
56. CHO J, Lee HJ, Hwang SJ, Min HY, et al
    The Interplay between Slow-Cycling, Chemoresistant Cancer Cells and Fibroblasts Creates a Proinflammatory Niche for Tumor Progression.
    Cancer Res. 2020;80:2257-2272.
    PubMed     Abstract available
    
    
    
57. CHEN CW, Fu M, Du ZH, Zhao F, et al
    Long Noncoding RNA MRPL23-AS1 Promoteoid Cystic Carcinoma Lung Metastasis.
    Cancer Res. 2020;80:2273-2285.
    PubMed     Abstract available
    
    
    May 2020
58. RODRIGUEZ-ANTOLIN C
    Artificial Intelligence Will Not Replace Health Professionals, but the Proper Use of Artificial Intelligence Will Make Health Professionals Better.
    Cancer Res. 2020;80:1912-1913.
    PubMed     Abstract available
    
    
    
59. STARRETT JH, Guernet AA, Cuomo ME, Poels KE, et al
    Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations.
    Cancer Res. 2020;80:2017-2030.
    PubMed     Abstract available
    
    
    April 2020
60. CHU W, Zhang X, Qi L, Fu Y, et al
    The EZH2-PHACTR2-AS1-ribosome axis induces genomic instability and promotes growth and metastasis in breast cancer.
    Cancer Res. 2020 Apr 20. pii: 0008-5472.CAN-19-3326.
    PubMed     Abstract available
    
    
    
61. ZHAO H, Iqbal NJ, Sukrithan V, Nicholas C, et al
    Targeted inhibition of the E3 ligase SCF-Skp2/Cks1 has antitumor activity in RB1-deficient human and mouse small cell lung cancer (SCLC).
    Cancer Res. 2020 Apr 7. pii: 0008-5472.CAN-19-2400.
    PubMed     Abstract available
    
    
    
62. YANG L, So JY, Skrypek N, Yang HH, et al
    Induction of DNMT3B by PGE2 and IL6 at distant metastatic sites promotes epigenetic modification and breast cancer colonization.
    Cancer Res. 2020 Apr 7. pii: 0008-5472.CAN-19-3339.
    PubMed     Abstract available
    
    
    March 2020
63. ROGERS RF, Walton MI, Cherry DL, Collins I, et al
    CHK1 inhibition is synthetically lethal with loss of B-family DNA polymerase function in human lung and colorectal cancer cells.
    Cancer Res. 2020 Mar 11. pii: 0008-5472.CAN-19-1372.
    PubMed     Abstract available
    
    
    
64. ZONG D, Gu J, Cavalcante GC, Yao W, et al
    BRD4 levels determine the response of human lung cancer cells to BET degraders that potently induce apoptosis through suppression of Mcl-1.
    Cancer Res. 2020 Mar 10. pii: 0008-5472.CAN-19-3674.
    PubMed     Abstract available
    
    
    
65. MENDER I, Batten K, Peyton M, Vemula A, et al
    SLC43A3 Is a Biomarker of Sensitivity to the Telomeric DNA Damage Mediator 6-Thio-2'-Deoxyguanosine.
    Cancer Res. 2020;80:929-936.
    PubMed     Abstract available
    
    
    
66. KARKI K, Wright GA, Mohankumar K, Jin UH, et al
    A Bis-Indole-Derived NR4A1 Antagonist Induces PD-L1 Degradation and Enhances Antitumor Immunity.
    Cancer Res. 2020;80:1011-1023.
    PubMed     Abstract available
    
    
    
67. BRINKER AE, Vivian CJ, Beadnell TC, Koestler DC, et al
    Mitochondrial Haplotype of the Host Stromal Microenvironment Alters Metastasis in a Non-cell Autonomous Manner.
    Cancer Res. 2020;80:1118-1129.
    PubMed     Abstract available
    
    
    February 2020
68. MARQUES M, Tranchant R, Risa-Ebri B, Suarez-Solis ML, et al
    Combined MEK and PI3K/p110beta Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features.
    Cancer Res. 2020;80:843-856.
    PubMed     Abstract available
    
    
    
69. JING B, Wang T, Sun B, Xu J, et al
    IL6/STAT3 Signaling Orchestrates Premetastatic Niche Formation and Immunosuppressive Traits in Lung.
    Cancer Res. 2020;80:784-797.
    PubMed     Abstract available
    
    
    
70. HEBERT JD, Myers SA, Naba A, Abbruzzese G, et al
    Proteomic profiling of the ECM of xenograft breast cancer metastases in different organs reveals distinct metastatic niches.
    Cancer Res. 2020 Feb 4. pii: 0008-5472.CAN-19-2961.
    PubMed     Abstract available
    
    
    
71. KONG T, Ahn R, Yang K, Zhu X, et al
    CD44 Promotes PD-L1 Expression and Its Tumor-Intrinsic Function in Breast and Lung Cancers.
    Cancer Res. 2020;80:444-457.
    PubMed     Abstract available
    
    
    January 2020
72. TAVERNA JA, Hung CN, DeArmond DT, Chen M, et al
    Single-cell Proteomic Profiling Identifies Combined AXL and JAK1 Inhibition as a Novel Therapeutic Strategy for Lung Cancer.
    Cancer Res. 2020 Jan 28. pii: 0008-5472.CAN-19-3183.
    PubMed     Abstract available
    
    
    
73. CRISTEA S, Coles GL, Hornburg D, Gershkovitz M, et al
    The MEK5-ERK5 kinase axis controls lipid metabolism in small cell lung cancer.
    Cancer Res. 2020 Jan 22. pii: 0008-5472.CAN-19-1027.
    PubMed     Abstract available
    
    
    
74. IKEMORI R, Gabasa M, Duch P, Vizoso M, et al
    Epigenetic SMAD3 Repression in Tumor-Associated Fibroblasts Impairs Fibrosis and Response to the Antifibrotic Drug Nintedanib in Lung Squamous Cell Carcinoma.
    Cancer Res. 2020;80:276-290.
    PubMed     Abstract available
    
    
    
75. WANG S, Rong R, Yang DM, Fujimoto J, et al
    Computational staining of pathology images to study the tumor microenvironment in lung cancer.
    Cancer Res. 2020 Jan 8. pii: 0008-5472.CAN-19-1629.
    PubMed     Abstract available
    
    
    November 2019
76. HAVEL JJ
    MEK Inhibitors in Lung Cancer-You Can Teach an Old Drug New Tricks.
    Cancer Res. 2019;79:5699-5701.
    PubMed     Abstract available
    
    
    
77. LOURENCO AR, Ban Y, Crowley MJ, Lee SB, et al
    Differential contributions of pre- and post- EMT tumor cells in breast cancer metastasis.
    Cancer Res. 2019 Nov 8. pii: 0008-5472.CAN-19-1427.
    PubMed     Abstract available
    
    
    
78. UMEH-GARCIA M, Simion C, Ho PY, Batra N, et al
    A Novel Bioengineered MicroRNA-127 Prodrug Suppresses The Growth And Metastatic Potential Of Triple Negative Breast Cancer Cells.
    Cancer Res. 2019 Nov 6. pii: 0008-5472.CAN-19-0656.
    PubMed     Abstract available
    
    
    October 2019
79. CHEN G, Park D, Magis AT, Behera M, et al
    Mcl-1 interacts with Akt to promote lung cancer progression.
    Cancer Res. 2019 Oct 29. pii: 0008-5472.CAN-19-0950.
    PubMed     Abstract available
    
    
    
80. CHIOU J, Chang YC, Tsai HF, Lin YF, et al
    Follistatin-like protein 1 inhibits lung cancer metastasis by preventing proteolytic activation of osteopontin.
    Cancer Res. 2019 Oct 25. pii: 0008-5472.CAN-19-0842.
    PubMed     Abstract available
    
    
    
81. BOWCOCK AM
    A Breath of Fresh Air: Opening up the Lung Cancer Genome.
    Cancer Res. 2019;79:4808-4810.
    PubMed     Abstract available
    
    
    
82. DONG SH, Li W, Wang L, Hu J, et al
    Histone-related genes are hypermethylated in lung cancer and hypermethylated HIST1H4F could serve as a pan-cancer biomarker.
    Cancer Res. 2019 Oct 1. pii: 0008-5472.CAN-19-1019.
    PubMed     Abstract available
    
    
    
83. MERRICK DT
    Sequencing the Events That Mediate Progression of Premalignant Lung Lesions.
    Cancer Res. 2019;79:4811-4813.
    PubMed     Abstract available
    
    
    
84. KRYSAN K, Tran LM, Grimes BS, Fishbein GA, et al
    The Immune Contexture Associates with the Genomic Landscape in Lung Adenomatous Premalignancy.
    Cancer Res. 2019;79:5022-5033.
    PubMed     Abstract available
    
    
    September 2019
85. HO MY, Liang SM, Hung SW, Liang CM, et al
    Retraction: MIG-7 Controls COX-2/PGE2-Mediated Lung Cancer Metastasis.
    Cancer Res. 2019;79:4553.
    PubMed    
    
    
    August 2019
86. CHUANG HC, Chang CC, Teng CF, Hsueh CH, et al
    MAP4K3/GLK promotes lung cancer metastasis by phosphorylating and activating IQGAP1.
    Cancer Res. 2019 Aug 20. pii: 0008-5472.CAN-19-1402.
    PubMed     Abstract available
    
    
    
87. VARTANIAN S, Lee J, Klijn C, Gnad F, et al
    ERBB3 and IGF1R signaling are required for Nrf2-dependent growth in KEAP1-mutant lung cancer.
    Cancer Res. 2019 Aug 15. pii: 0008-5472.CAN-18-2086.
    PubMed     Abstract available
    
    
    July 2019
88. XIE M, Zheng H, Madan-Lala R, Dai W, et al
    MEK inhibition modulates cytokine response to mediate therapeutic efficacy in lung cancer.
    Cancer Res. 2019 Jul 30. pii: 0008-5472.CAN-19-0698.
    PubMed     Abstract available
    
    
    
89. CHANG YC, Chiou J, Yang YF, Su CY, et al
    Therapeutic Targeting of Aldolase A Interactions Inhibits Lung Cancer Metastasis and Prolongs Survival.
    Cancer Res. 2019 Jul 29. pii: 0008-5472.CAN-18-4080.
    PubMed     Abstract available
    
    
    
90. ZHENG ZQ, Li ZX, Zhou GQ, Lin L, et al
    Long non-coding RNA FAM225A promotes nasopharyngeal carcinoma tumorigenesis and metastasis by acting as ceRNA to sponge miR-590-3p/miR-1275 and upregulate ITGB3.
    Cancer Res. 2019 Jul 22. pii: 0008-5472.CAN-19-0799.
    PubMed     Abstract available
    
    
    June 2019
91. KAMAL Y, Schmit SL, Hoehn HJ, Amos CI, et al
    Transcriptomic differences between primary colorectal adenocarcinomas and distant metastases reveal metastatic colorectal cancer subtypes.
    Cancer Res. 2019 Jun 25. pii: 0008-5472.CAN-18-3945.
    PubMed     Abstract available
    
    
    
92. ACHARYA S, Yao J, Li P, Zhang C, et al
    Sphingosine-kinase-1 signaling promotes metastasis of triple-negative breast cancer.
    Cancer Res. 2019 Jun 25. pii: 0008-5472.CAN-18-3803.
    PubMed     Abstract available
    
    
    
93. WANG Z, Tu K, Xia L, Luo K, et al
    The Open Chromatin Landscape of Non-small Cell Lung Carcinoma.
    Cancer Res. 2019 Jun 17. pii: 0008-5472.CAN-18-3663.
    PubMed     Abstract available
    
    
    
94. DAVALOS V, Esteller M
    Disruption of Long Noncoding RNAs Targets Cancer Hallmark Pathways in Lung Tumorigenesis.
    Cancer Res. 2019;79:3028-3030.
    PubMed     Abstract available
    
    
    
95. SHAHABI S, Kumaran V, Castillo J, Cong Z, et al
    LINC00261 Is an Epigenetically Regulated Tumor Suppressor Essential for Activation of the DNA Damage Response.
    Cancer Res. 2019;79:3050-3062.
    PubMed     Abstract available
    
    
    May 2019
96. SASAKI Y, Fujimori H, Hozumi M, Onodera T, et al
    Dysfunction of poly(ADP-ribose) glycohydrolase induces a synthetic lethal effect in dual specificity phosphatase 22-deficient lung cancer cells.
    Cancer Res. 2019 May 29. pii: 0008-5472.CAN-18-1037.
    PubMed     Abstract available
    
    
    
97. SONG M, Ping Y, Zhang K, Yang L, et al
    Low-dose IFN-gamma induces tumor cell stemness in the tumor microenvironment of non-small cell lung cancer.
    Cancer Res. 2019 May 13. pii: 0008-5472.CAN-19-0596.
    PubMed     Abstract available
    
    
    April 2019
98. KONDO Y
    Genome-Epigenome-Senescence: Is TET1 a Caretaker of p53-Injured Lung Cancer Cells?
    Cancer Res. 2019;79:1751-1752.
    PubMed     Abstract available
    
    
    
99. PAIDI SK, Diaz PM, Dadgar S, Jenkins SV, et al
    Label-Free Raman Spectroscopy Reveals Signatures of Radiation Resistance in the Tumor Microenvironment.
    Cancer Res. 2019;79:2054-2064.
    PubMed     Abstract available
    
    
    
100. BUSHNELL GG, Hardas TP, Hartfield RM, Zhang Y, et al
     Biomaterial Scaffolds Recruit an Aggressive Population of Metastatic Tumor Cells In Vivo.
     Cancer Res. 2019;79:2042-2053.
     PubMed     Abstract available
     
     
     
101. LEWIS DM, Pruitt H, Jain N, Ciccaglione M, et al
     A Feedback Loop between Hypoxia and Matrix Stress Relaxation Increases Oxygen-Axis Migration and Metastasis in Sarcoma.
     Cancer Res. 2019;79:1981-1995.
     PubMed     Abstract available
     
     
     
102. ZHAO J, Feng M, Liu D, Liu H, et al
     Antagonism between HtrA3 and TGF-beta1 Contributes to Metastasis in Non-small-cell Lung Cancer.
     Cancer Res. 2019 Apr 2. pii: 0008-5472.CAN-18-2507.
     PubMed     Abstract available
     
     
     
103. RAMAMOORTHY P, Thomas SM, Kaushik G, Subramaniam D, et al
     Metastatic Tumor-in-a-Dish, a Novel Multicellular Organoid to Study Lung Colonization and Predict Therapeutic Response.
     Cancer Res. 2019;79:1681-1695.
     PubMed     Abstract available
     
     
     
104. VUONG L, Kouverianou E, Rooney CM, McHugh BJ, et al
     An Orally Active Galectin-3 Antagonist Inhibits Lung Adenocarcinoma Growth and Augments Response to PD-L1 Blockade.
     Cancer Res. 2019;79:1480-1492.
     PubMed     Abstract available
     
     
     March 2019
105. SOHONI S, Ghosh P, Wang T, Kalainayakan SP, et al
     Elevated heme synthesis and uptake underpin intensified oxidative metabolism and tumorigenic functions in non-small cell lung cancer cells.
     Cancer Res. 2019 Mar 22. pii: 0008-5472.CAN-18-2156.
     PubMed     Abstract available
     
     
     
106. ZOU T, Meyerson M
     Circulating Tumor DNA Provides a Sneak Peek into Treatment Responses in Non-Small Cell Lung Cancer.
     Cancer Res. 2019;79:1038-1040.
     PubMed     Abstract available
     
     
     
107. UDYAVAR AR, Wooten DJ, Hoeksema M, Bansal M, et al
     Correction: Novel Hybrid Phenotype Revealed in Small Cell Lung Cancer by a Transcription Factor Network Model That Can Explain Tumor Heterogeneity.
     Cancer Res. 2019;79:1014.
     PubMed    
     
     
     February 2019
108. HALLAHAN D
     ATM Inhibition Sensitizes Tumors to High-Dose Irradiation.
     Cancer Res. 2019;79:704-705.
     PubMed     Abstract available
     
     
     
109. FUKUDA K, Takeuchi S, Arai S, Katayama R, et al
     Epithelial-to-mesenchymal transition is a mechanism of ALK inhibitor resistance in lung cancer independent of ALK mutation status.
     Cancer Res. 2019 Feb 8. pii: 0008-5472.CAN-18-2052.
     PubMed     Abstract available
     
     
     
110. YAN Y, Sun N, Wang H, Kobayashi M, et al
     Whole genome-derived tiled peptide arrays detect pre-diagnostic autoantibody signatures in non-small cell lung cancer.
     Cancer Res. 2019 Feb 5. pii: 0008-5472.CAN-18-1536.
     PubMed     Abstract available
     
     
     
111. MURTUZA A, Bulbul A, Shen JP, Keshavarzian P, et al
     Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer.
     Cancer Res. 2019 Feb 4. pii: 0008-5472.CAN-18-1281.
     PubMed     Abstract available
     
     
     
112. ROMAN M, Lopez I, Guruceaga E, Baraibar I, et al
     Inhibitor of Differentiation-1 Sustains Mutant KRAS-Driven Progression, Maintenance, and Metastasis of Lung Adenocarcinoma via Regulation of a FOSL1 Network.
     Cancer Res. 2019;79:625-638.
     PubMed     Abstract available
     
     
     
113. NEEL DS, Allegakoen DV, Olivas V, Mayekar MK, et al
     Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins.
     Cancer Res. 2019;79:546-556.
     PubMed     Abstract available
     
     
     January 2019
114. LI YP, Sin TK, Zhu JZ, Zhang G, et al
     p300 mediates muscle wasting in Lewis lung carcinoma.
     Cancer Res. 2019 Jan 31. pii: 0008-5472.CAN-18-1653.
     PubMed     Abstract available
     
     
     
115. JIANG Y, Chen T, Wang T, Liang W, et al
     PAK4 phosphorylates fumarase and blocks TGF-beta-induced cell growth arrest in lung cancer cells.
     Cancer Res. 2019 Jan 25. pii: 0008-5472.CAN-18-2575.
     PubMed     Abstract available
     
     
     
116. SHIELDS BD, Koss B, Taylor EM, Storey AJ, et al
     Loss of E-cadherin inhibits CD103 anti-tumor activity and reduces checkpoint blockade responsiveness in melanoma.
     Cancer Res. 2019 Jan 23. pii: 0008-5472.CAN-18-1722.
     PubMed     Abstract available
     
     
     
117. DYER A, Schoeps B, Frost S, Jakeman P, et al
     Antagonism of Glycolysis and Reductive Carboxylation of Glutamine Potentiates Activity of Oncolytic Adenoviruses in Cancer Cells.
     Cancer Res. 2019;79:331-345.
     PubMed     Abstract available
     
     
     
118. FILIPCZAK PT, Leng S, Tellez CS, Do KC, et al
     p53-suppressed oncogene TET1 prevents cellular aging in lung cancer.
     Cancer Res. 2019 Jan 8. pii: 0008-5472.CAN-18-1234.
     PubMed     Abstract available
     
     
     
119. KOSSENKOV AV, Qureshi R, Dawany NB, Wickramasinghe J, et al
     A Gene Expression Classifier from Whole Blood Distinguishes Benign from Malignant Lung Nodules Detected by Low-Dose CT.
     Cancer Res. 2019;79:263-273.
     PubMed     Abstract available
     
     
     
120. WERFEL TA, Elion DL, Rahman B, Hicks DJ, et al
     Treatment-Induced Tumor Cell Apoptosis and Secondary Necrosis Drive Tumor Progression in the Residual Tumor Microenvironment through MerTK and IDO1.
     Cancer Res. 2019;79:171-182.
     PubMed     Abstract available
     
     
     
121. YAN X, Zhang X, Wang L, Zhang R, et al
     Inhibition of Thioredoxin/Thioredoxin Reductase Induces Synthetic Lethality in Lung Cancers with Compromised Glutathione Homeostasis.
     Cancer Res. 2019;79:125-132.
     PubMed     Abstract available
     
     
     December 2018
122. PHALLEN J, Leal A, Woodward BD, Forde PM, et al
     Early Noninvasive Detection of Response to Targeted Therapy in Non-Small Cell Lung Cancer.
     Cancer Res. 2018 Dec 20. pii: 0008-5472.CAN-18-1082.
     PubMed     Abstract available
     
     
     
123. ANAGNOSTOU V, Forde PM, White JR, Niknafs N, et al
     Dynamics of tumor and immune responses during immune checkpoint blockade in non-small cell lung cancer.
     Cancer Res. 2018 Dec 12. pii: 0008-5472.CAN-18-1127.
     PubMed     Abstract available
     
     
     November 2018
124. LAN J, Sun L, Xu F, Liu L, et al
     M2 macrophage-derived exosomes promote cell migration and invasion in colon cancer.
     Cancer Res. 2018 Nov 6. pii: 0008-5472.CAN-18-0014.
     PubMed     Abstract available
     
     
     
125. WANG J, Wang D, Niu X, Wang Z, et al
     Multiregion sequencing reveals the genetic heterogeneity and evolutionary history of osteosarcoma and matched pulmonary metastases.
     Cancer Res. 2018 Nov 2. pii: 0008-5472.CAN-18-1086.
     PubMed     Abstract available
     
     
     October 2018
126. EL KADI N, Wang L, Davis A, Korkaya H, et al
     The EGFR T790M mutation is acquired through AICDA-mediated deamination of 5-methylcytosine following TKI treatment in lung cancer.
     Cancer Res. 2018 Oct 17. pii: 0008-5472.CAN-17-3370.
     PubMed     Abstract available
     
     
     August 2018
127. HUANG F, Shi Q, Li Y, Xu L, et al
     HER2/EGFR-AKT signaling switches TGF-beta from inhibiting cell proliferation to promoting cell migration in breast cancer.
     Cancer Res. 2018 Aug 31. pii: 0008-5472.CAN-18-0136.
     PubMed     Abstract available
     
     
     
128. ZHOU Y, Shurin GV, Zhong H, Bunimovich YL, et al
     Schwann cells augment cell spreading and metastasis of lung cancer.
     Cancer Res. 2018 Aug 22. pii: 0008-5472.CAN-18-1702.
     PubMed     Abstract available
     
     
     
129. MARTIN-SANCHEZ JC, Lunet N, Gonzalez-Marron A, Lidon-Moyano C, et al
     Projections in Breast and Lung Cancer Mortality among Women: A Bayesian Analysis of 52 Countries Worldwide.
     Cancer Res. 2018;78:4436-4442.
     PubMed     Abstract available
     
     
     June 2018
130. BROUWER AF, Eisenberg MC, Meza R
     Case Studies of Gastric, Lung, and Oral Cancer Connect Etiologic Agent Prevalence to Cancer Incidence.
     Cancer Res. 2018;78:3386-3396.
     PubMed     Abstract available
     
     
     May 2018
131. MEDER L, Schuldt P, Thelen M, Schmitt A, et al
     Combined VEGF and PD-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell lung cancer.
     Cancer Res. 2018 May 18. pii: 0008-5472.CAN-17-2176.
     PubMed     Abstract available
     
     
     April 2018
132. HEIM L, Friedrich J, Engelhardt M, Trufa DI, et al
     NFATc1 promotes anti-tumoral effector functions and memory CD8+ T cell differentiation during non-small cell lung cancer development.
     Cancer Res. 2018 Apr 24. pii: 0008-5472.CAN-17-3297.
     PubMed     Abstract available
     
     
     
133. SU W, Feng S, Chen X, Yang X, et al
     Silencing of long non-coding RNA MIR22HG triggers cell survival/death signaling via oncogenes YBX1, MET, and p21 in lung cancer.
     Cancer Res. 2018 Apr 18. pii: 0008-5472.CAN-18-0222.
     PubMed     Abstract available
     
     
     
134. LU YX, Ju HQ, Liu ZX, Chen DL, et al
     ME1 Regulates NADPH Homeostasis to Promote Gastric Cancer Growth and Metastasis.
     Cancer Res. 2018;78:1972-1985.
     PubMed     Abstract available
     
     
     March 2018
135. SILINA K, Soltermann A, Attar FM, Casanova R, et al
     Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma.
     Cancer Res. 2018;78:1308-1320.
     PubMed     Abstract available
     
     
     February 2018
136. MAKINOSHIMA H, Umemura S, Suzuki A, Nakanishi H, et al
     Metabolic determinants of sensitivity to phosphatidylinositol 3-kinase pathway inhibitor in small-cell lung carcinoma.
     Cancer Res. 2018 Feb 28. pii: 0008-5472.CAN-17-2109.
     PubMed     Abstract available
     
     
     
137. DE S, Lindner DJ, Coleman C, Wildey G, et al
     The FACT inhibitor CBL0137 synergizes with cisplatin in small cell lung cancer by increasing NOTCH1 expression and targeting tumor-initiating cells.
     Cancer Res. 2018 Feb 13. pii: 0008-5472.CAN-17-1920.
     PubMed     Abstract available
     
     
     January 2018
138. CARONNI N, Simoncello F, Stafetta F, Guarnaccia C, et al
     Downregulation of membrane trafficking proteins and lactate conditioning determine loss of dendritic cell function in lung cancer.
     Cancer Res. 2018 Jan 23. pii: 0008-5472.CAN-17-1307.
     PubMed     Abstract available
     
     
     
139. DOPESO H, Jiao HK, Cuesta AM, Henze AT, et al
     PHD3 controls lung cancer metastasis and resistance to EGFR inhibitors through TGFalpha.
     Cancer Res. 2018 Jan 16. pii: 0008-5472.CAN-17-1346.
     PubMed     Abstract available
     
     
     
140. YANG Y, Leonard M, Zhang Y, Zhao D, et al
     HER2-Driven Breast Tumorigenesis Relies upon Interactions of the Estrogen Receptor with Coactivator MED1.
     Cancer Res. 2018;78:422-435.
     PubMed     Abstract available
     
     
     
141. TIMANER M, Letko-Khait N, Kotsofruk R, Benguigui M, et al
     Therapy-educated mesenchymal stem cells enrich for tumor initiating cells.
     Cancer Res. 2018 Jan 4. pii: 0008-5472.CAN-17-1547.
     PubMed     Abstract available
     
     
     
142. ARNST KE, Wang Y, Hwang DJ, Xue Y, et al
     A Potent, Metabolically Stable Tubulin Inhibitor Targets the Colchicine Binding Site and Overcomes Taxane Resistance.
     Cancer Res. 2018;78:265-277.
     PubMed     Abstract available
     
     
     December 2017
143. ADELAIYE-OGALA R, Budka J, Damayanti NP, Arrington J, et al
     EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming.
     Cancer Res. 2017;77:6651-6666.
     PubMed     Abstract available
     
     
     November 2017
144. EMERSON MA, Banegas MP, Chawla N, Achacoso N, et al
     Disparities in Prostate, Lung, Breast, and Colorectal Cancer Survival and Comorbidity Status among Urban American Indians and Alaskan Natives.
     Cancer Res. 2017 Nov 29. pii: 0008-5472.CAN-17-0429.
     PubMed     Abstract available
     
     
     
145. HOU P, Li L, Chen F, Chen Y, et al
     PTBP3-mediated regulation of ZEB1 mRNA stability promotes epithelial-mesenchymal transition in breast cancer.
     Cancer Res. 2017 Nov 29. pii: 0008-5472.CAN-17-0883.
     PubMed     Abstract available
     
     
     
146. BYRD TT, Fousek K, Pignata A, Szot C, et al
     TEM8/ANTXR1-specific CAR T cells as a targeted therapy for triple-negative breast cancer.
     Cancer Res. 2017 Nov 28. pii: 0008-5472.CAN-16-1911.
     PubMed     Abstract available
     
     
     
147. SIVAKUMAR S, Lucas FAS, McDowell TL, Lang W, et al
     Genomic Landscape of Atypical Adenomatous Hyperplasia Reveals Divergent Modes to Lung Adenocarcinoma.
     Cancer Res. 2017;77:6119-6130.
     PubMed     Abstract available
     
     
     
148. KWAK JW, Laskowski J, Li HY, McSharry MV, et al
     Complement activation via a C3a receptor pathway alters CD4+ T lymphocytes and mediates lung cancer progression.
     Cancer Res. 2017 Nov 8. pii: canres.0240.2017.
     PubMed     Abstract available
     
     
     
149. WANG W, Huang L, Jin JY, Jolly S, et al
     IDO Immune Status after Chemoradiation May Predict Survival in Lung Cancer Patients.
     Cancer Res. 2017 Nov 8. pii: canres.2995.2017.
     PubMed     Abstract available
     
     
     
150. HUANG H, Zhang W, Pan Y, Gao Y, et al
     YAP Suppresses Lung Squamous Cell Carcinoma Progression via Deregulation of the DNp63-GPX2 Axis and ROS Accumulation.
     Cancer Res. 2017;77:5769-5781.
     PubMed     Abstract available
     
     
     
151. HUA KT, Hong JB, Sheen YS, Huang HY, et al
     MicroRNA-519d promotes melanoma progression by downregulating EphA4.
     Cancer Res. 2017 Nov 1. pii: canres.1933.2017.
     PubMed     Abstract available
     
     
     October 2017
152. ZUO H, Ueland PM, Midttun O, Vollset SE, et al
     Results from the European Prospective Investigation into Cancer and Nutrition (EPIC) link vitamin B6 catabolism and lung cancer risk.
     Cancer Res. 2017 Oct 25. pii: canres.1923.2017.
     PubMed     Abstract available
     
     
     September 2017
153. KIDDER BL, He R, Wangsa D, Padilla-Nash HM, et al
     SMYD5 controls heterochromatin and chromosome integrity during embryonic stem cell differentiation.
     Cancer Res. 2017 Sep 26. pii: canres.0828.2017.
     PubMed     Abstract available
     
     
     
154. SHUKLA V, Rao M, Zhang H, Beers J, et al
     ASXL3 is a Novel Pluripotency Factor in Human Respiratory Epithelial Cells and a Potential Therapeutic Target in Small Cell Lung Cancer.
     Cancer Res. 2017 Sep 21. pii: canres.0570.2017.
     PubMed     Abstract available
     
     
     
155. YAO M, Yu T, Zhao YJ, Hu Z, et al
     MetaLnc9 facilitates lung cancer metastasis via a PGK1-activated AKT/mTOR pathway.
     Cancer Res. 2017 Sep 18. pii: canres.0671.2017.
     PubMed     Abstract available
     
     
     
156. LIU Y, Li Y, Wang X, Liu F, et al
     Gemcitabine and Chk1 Inhibitor AZD7762 Synergistically Suppress the Growth of Lkb1-Deficient Lung Adenocarcinoma.
     Cancer Res. 2017;77:5068-5076.
     PubMed     Abstract available
     
     
     
157. MURLIDHAR V, Reddy RM, Fouladdel S, Zhao L, et al
     Poor Prognosis Indicated by Venous Circulating Tumor Cell Clusters in Early-Stage Lung Cancers.
     Cancer Res. 2017;77:5194-5206.
     PubMed     Abstract available
     
     
     
158. MCFARLAND CD, Yaglom JA, Wojtkowiak JW, Scott JG, et al
     The Damaging Effect of Passenger Mutations on Cancer Progression.
     Cancer Res. 2017;77:4763-4772.
     PubMed     Abstract available
     
     
     
159. KACHLER K, Bailer M, Heim L, Schumacher F, et al
     Enhanced acid sphingomyelinase activity drives immune evasion and tumor growth in non-small cell lung carcinoma.
     Cancer Res. 2017 Sep 7. pii: canres.3313.2016.
     PubMed     Abstract available
     
     
     
160. TAKAGI S, Ishikawa Y, Mizutani A, Iwasaki S, et al
     LSD1 Inhibitor T-3775440 Inhibits SCLC Cell Proliferation by Disrupting LSD1 Interactions with SNAG Domain Proteins INSM1 and GFI1B.
     Cancer Res. 2017;77:4652-4662.
     PubMed     Abstract available
     
     
     August 2017
161. KASIRI S, Shao C, Chen B, Wilson AN, et al
     GLI1 Blockade Potentiates the Antitumor Activity of PI3K Antagonists in Lung Squamous Cell Carcinoma.
     Cancer Res. 2017;77:4448-4459.
     PubMed     Abstract available
     
     
     July 2017
162. TILL J, Yoon C, Kim BJ, Roby KC, et al
     Oncogenic KRAS and p53 loss drive gastric tumorigenesis in mice that can be attenuated by E-cadherin expression.
     Cancer Res. 2017 Jul 31. pii: canres.0061.2017.
     PubMed     Abstract available
     
     
     
163. DU W, Xu X, Niu Q, Zhang X, et al
     Spi-B-mediated silencing of Claudin-2 promotes early dissemination of lung cancer cells from primary tumors.
     Cancer Res. 2017 Jul 28. pii: canres.0020.2017.
     PubMed     Abstract available
     
     
     
164. SALVADOR F, Martin A, Lopez-Menendez C, Moreno-Bueno G, et al
     Lysyl oxidase-like protein LOXL2 promotes lung metastasis of breast cancer.
     Cancer Res. 2017 Jul 18. pii: canres.3152.2016.
     PubMed     Abstract available
     
     
     
165. COOPER JM, Ou YH, McMillan E, Vaden RM, et al
     TBK1 Provides Context-Selective Support of the Activated AKT/mTOR Pathway in Lung Cancer.
     Cancer Res. 2017 Jul 17. pii: canres.0829.2017.
     PubMed     Abstract available
     
     
     
166. JERMYN M, Mercier J, Aubertin K, Desroches J, et al
     Highly Accurate Detection of Cancer In Situ with Intraoperative, Label-Free, Multimodal Optical Spectroscopy.
     Cancer Res. 2017;77:3942-3950.
     PubMed     Abstract available
     
     
     
167. JIANG H, Rivera-Molina Y, Gomez-Manzano C, Clise-Dwyer K, et al
     Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination.
     Cancer Res. 2017;77:3894-3907.
     PubMed     Abstract available
     
     
     
168. CHAKRABARTI S, Michor F
     Pharmacokinetics and Drug Interactions Determine Optimum Combination Strategies in Computational Models of Cancer Evolution.
     Cancer Res. 2017;77:3908-3921.
     PubMed     Abstract available
     
     
     
169. NG KY, Chan LH, Chai S, Tong M, et al
     TP53INP1 down-regulation activates a p73-dependent DUSP10/ERK signaling pathway to promote metastasis of hepatocellular carcinoma.
     Cancer Res. 2017 Jul 3. pii: canres.3456.2016.
     PubMed     Abstract available
     
     
     June 2017
170. RICHER AL, Cala JM, O'Brien K, Carson VM, et al
     WEE1 kinase inhibitor AZD1775 has pre-clinical efficacy in LKB1-deficient non-small cell lung cancer.
     Cancer Res. 2017 Jun 26. pii: canres.3565.2016.
     PubMed     Abstract available
     
     
     
171. YOUNG A, Ngiow SF, Madore J, Reinhardt J, et al
     Targeting adenosine in BRAF-mutant melanoma reduces tumor growth and metastasis.
     Cancer Res. 2017 Jun 26. pii: canres.0393.2017.
     PubMed     Abstract available
     
     
     
172. TRIPATHI SC, Fahrmann JF, Celiktas M, Aguilar M, et al
     MCAM mediates chemoresistance in small cell lung cancer via the PI3K/AKT/SOX2 signaling pathway.
     Cancer Res. 2017 Jun 23. pii: canres.2874.2016.
     PubMed     Abstract available
     
     
     May 2017
173. RIOS VELAZQUEZ E, Parmar C, Liu Y, Coroller TP, et al
     Somatic mutations drive distinct imaging phenotypes in lung cancer.
     Cancer Res. 2017 May 31. pii: canres.0122.2017.
     PubMed     Abstract available
     
     
     
174. YE M, Zhang Y, Zhang X, Zhang JB, et al
     Targeting FBW7 as a strategy to overcome resistance to targeted therapy in non-small cell lung cancer.
     Cancer Res. 2017 May 18. pii: canres.3470.2016.
     PubMed     Abstract available
     
     
     
175. SEN T, Tong P, Stewart CA, Cristea S, et al
     CHK1 inhibition in small cell lung cancer produces single-agent activity in biomarker-defined disease subsets and combination activity with cisplatin or olaparib.
     Cancer Res. 2017 May 10. pii: canres.3409.2016.
     PubMed     Abstract available
     
     
     
176. PRAT A, Navarro A, Pare L, Reguart N, et al
     Immune-related gene expression profiling after PD-1 blockade in non-small cell lung carcinoma, head and neck squamous cell carcinoma and melanoma.
     Cancer Res. 2017 May 9. pii: canres.3556.2017.
     PubMed     Abstract available
     
     
     
177. SHARMA SK, Pourat J, Abdel-Atti D, Carlin SD, et al
     Non-invasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer.
     Cancer Res. 2017 May 9. pii: canres.0299.2017.
     PubMed     Abstract available
     
     
     
178. PAILLER E, Oulhen M, Borget I, Remon J, et al
     Circulating Tumor Cells with Aberrant ALK Copy Number Predict Progression-Free Survival during Crizotinib Treatment in ALK-Rearranged Non-Small Cell Lung Cancer Patients.
     Cancer Res. 2017;77:2222-2230.
     PubMed     Abstract available
     
     
     April 2017
179. ICHIHARA E, Westover D, Meador CB, Yan Y, et al
     SFK/FAK signaling attenuates osimertinib efficacy in both drug-sensitive and drug-resistant models of EGFR-mutant lung cancer.
     Cancer Res. 2017 Apr 17. pii: canres.2300.2016.
     PubMed     Abstract available
     
     
     
180. ZHANG Y, Xu W, Guo H, Zhang Y, et al
     NOTCH1 Signaling Regulates Self-renewal and Platinum Chemoresistance of Cancer Stem-like Cells in Human Non-small Cell Lung Cancer.
     Cancer Res. 2017 Apr 17. pii: canres.1633.2016.
     PubMed     Abstract available
     
     
     
181. STEVENS LE, Cheung WKC, Adua SJ, Arnal-Estape A, et al
     Extracellular Matrix Receptor Expression in Subtypes of Lung Adenocarcinoma Potentiates Outgrowth of Micrometastases.
     Cancer Res. 2017;77:1905-1917.
     PubMed     Abstract available
     
     
     
182. WEN H, Chiu YF, Kuo MH, Lee KL, et al
     Expression of neuroendocrine factor VGF in lung cancer cells confers resistance to EGFR kinase inhibitors and triggers epithelial-to-mesenchymal transition.
     Cancer Res. 2017 Apr 5. pii: canres.3168.2016.
     PubMed     Abstract available
     
     
     
183. WALTER DM, Venancio OS, Buza EL, Tobias JW, et al
     Systematic In Vivo Inactivation of Chromatin-Regulating Enzymes Identifies Setd2 as a Potent Tumor Suppressor in Lung Adenocarcinoma.
     Cancer Res. 2017;77:1719-1729.
     PubMed     Abstract available
     
     
     March 2017
184. LIAO L, Song M, Li X, Tang L, et al
     E3 ubiquitin ligase UBR5 drives the growth and metastasis of triple negative breast cancer.
     Cancer Res. 2017 Mar 22. pii: canres.2409.2016.
     PubMed     Abstract available
     
     
     January 2017
185. HAN SY, Ko A, Kitano H, Choi CH, et al
     Molecular Chaperone HSP90 Is Necessary to Prevent Cellular Senescence via Lysosomal Degradation of p14ARF.
     Cancer Res. 2017;77:343-354.
     PubMed     Abstract available
     
     
     
186. KAUFMAN JM, Yamada T, Park K, Timmers CD, et al
     A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung Adenocarcinoma.
     Cancer Res. 2017;77:153-163.
     PubMed     Abstract available
     
     
     
187. ZHOU X, Updegraff BL, Guo Y, Peyton M, et al
     PROTOCADHERIN 7 Acts through SET and PP2A to Potentiate MAPK Signaling by EGFR and KRAS during Lung Tumorigenesis.
     Cancer Res. 2017;77:187-197.
     PubMed     Abstract available
     
     
     
188. MAMAN S, Sagi-Assif O, Yuan W, Ginat R, et al
     The Beta Subunit of Hemoglobin (HBB2/HBB) Suppresses Neuroblastoma Growth and Metastasis.
     Cancer Res. 2017;77:14-26.
     PubMed     Abstract available
     
     
     November 2016
189. DOWER CM, Bhat N, Wang EW, Wang HG, et al
     Selective Reversible Inhibition of Autophagy in Hypoxic Breast Cancer Cells Promotes Pulmonary Metastasis.
     Cancer Res. 2016 Nov 15. doi: 10.1158/0008-5472.CAN-15-3458.
     PubMed     Abstract available
     
     
     
190. PAIDI SK, Rizwan A, Zheng C, Cheng M, et al
     Label-Free Raman Spectroscopy Detects Stromal Adaptations in Premetastatic Lungs Primed by Breast Cancer.
     Cancer Res. 2016 Nov 15. doi: 10.1158/0008-5472.CAN-16-1862.
     PubMed     Abstract available
     
     
     August 2016
191. YOLDI G, Pellegrini P, Trinidad EM, Cordero A, et al
     RANK signaling blockade reduces breast cancer recurrence by inducing tumor cell differentiation.
     Cancer Res. 2016 Aug 1. pii: canres.2745.2015.
     PubMed     Abstract available
     
     
     April 2016
192. BOUTET M, Gauthier L, Leclerc M, Gros G, et al
     TGFbeta Signaling Intersects with CD103 Integrin Signaling to Promote T-Lymphocyte Accumulation and Antitumor Activity in the Lung Tumor Microenvironment.
     Cancer Res. 2016;76:1757-69.
     PubMed     Abstract available
     
     
     
193. FUCIKOVA J, Becht E, Iribarren K, Goc J, et al
     Calreticulin Expression in Human Non-Small Cell Lung Cancers Correlates with Increased Accumulation of Antitumor Immune Cells and Favorable Prognosis.
     Cancer Res. 2016;76:1746-56.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: